Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC-2)

NCT07715734 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07715734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07715734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC-2)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2031
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma (cscc), kidney transplant, kidney transplant recipient